Trenkwalder P, Hendricks P, Hense H W
Department of Internal Medicine, Starnberg Hospital, Ludwig Maximilian University Munich, Germany.
J Hypertens. 1998 Aug;16(8):1113-6. doi: 10.1097/00004872-199816080-00005.
To assess the relationship between use of calcium antagonists and incidence of fatal or non-fatal cancer over 3 years in the Starnberg Study on Epidemiology of Parkinsonism and Hypertension in the Elderly (STEPHY) population.
A prospective cohort study with follow-up analysis after 3 years.
In 1992 STEPHY workers investigated the total population aged > 65 years (n = 1190) of two villages in Bavaria, Germany. With 982 participants (response rate 83%) the prevalence of 'actual' hypertension (blood pressure > or = 160/95 mmHg or treatment) was 53%. Of all hypertensives (n = 491), 54% were being treated, 28% (n = 137) with calcium antagonists. Participants with a history of cancer or manifest cancer were excluded from further analysis. In 1995 in STEPHY II, the 3-year follow-up, we assessed total mortality (including cases of fatal cancer), cardiovascular events and cases of non-fatal cancer between 1992 and 1995. The evaluation included a second interview, use of case records of general practitioners and hospitals and analysis of the official death certificates. The total incidence of fatal and non-fatal cancer (a combined end point) was calculated for participants treated with calcium antagonists and those not taking calcium antagonists.
Total mortality over 3 years was 12.1 % (n = 119). There were 22 deaths due to cancer and 75 cases of newly diagnosed non-fatal cancer. The combined incidence of fatal and non-fatal cancer (primary end point) was 10.9% (n = 15) for participants treated with calcium antagonists and 9.7% (n = 82) for those not taking calcium antagonists (odds ratio 1.12, 95% confidence interval 0.7-1.8). There was also no significant difference between the incidences of fatal cancer (2.2% in both groups), non-fatal cancer (12.5% for participants treated with calcium antagonists and 10.8% for those not taking calcium antagonists) and total mortality (14.6% for participants taking calcium antagonists and 11.7% for those not treated with calcium antagonists).
Use of calcium antagonists does not increase the risk of fatal or non-fatal cancer over 3 years in an elderly mid-European population.
在施塔恩贝格老年帕金森病与高血压流行病学研究（STEPHY）人群中，评估钙拮抗剂的使用与3年内致命性或非致命性癌症发病率之间的关系。
一项前瞻性队列研究，3年后进行随访分析。
1992年，STEPHY研究人员对德国巴伐利亚州两个村庄中年龄大于65岁的总人口（n = 1190）进行了调查。982名参与者（应答率83%）中，“实际”高血压（血压≥160/95 mmHg或接受治疗）的患病率为53%。在所有高血压患者（n = 491）中，54%正在接受治疗，其中28%（n = 137）使用钙拮抗剂治疗。有癌症病史或已确诊癌症的参与者被排除在进一步分析之外。1995年，在STEPHY II研究（3年随访）中，我们评估了1992年至1995年间的总死亡率（包括致命性癌症病例）、心血管事件和非致命性癌症病例。评估包括第二次访谈、使用全科医生和医院的病例记录以及分析官方死亡证明。计算了使用钙拮抗剂治疗的参与者和未服用钙拮抗剂的参与者中致命性和非致命性癌症的总发病率（一个综合终点）。
3年总死亡率为12.1%（n = 119）。有22例死于癌症，75例新诊断为非致命性癌症。使用钙拮抗剂治疗的参与者中，致命性和非致命性癌症的综合发病率（主要终点）为10.9%（n = 15），未服用钙拮抗剂的参与者为9.7%（n = 82）（比值比1.12，95%置信区间为０.7 - 1.8）。致命性癌症发病率（两组均为2.2%）、非致命性癌症发病率（使用钙拮抗剂治疗的参与者为12.5%，未服用钙拮抗剂的参与者为10.8%）和总死亡率（服用钙拮抗剂的参与者为14.6%，未接受钙拮抗剂治疗的参与者为11.7%）之间也没有显著差异。
在欧洲中部老年人群中，使用钙拮抗剂在3年内不会增加致命性或非致命性癌症的风险。
